Author:
Díaz-Alvarez Laura,López-Cortés Georgina I.,Pérez-Figueroa Erandi
Abstract
Rare cancers represent only 5% of newly diagnosed malignancies. However, in some cases, they account for up to 50% of the deaths attributed to cancer in their corresponding organ. Part of the reason is that treatment options are generally quite limited, non-specific, and very often, only palliative. Needless to say, research for tailored treatments is warranted. Molecules that exert immunomodulation of the tumor microenvironment are attractive drug targets. One such group is galectins. Thus, in this review we summarize the current knowledge about galectin-mediated immunomodulation in rare cancers, highlighting the research opportunities in each case.
Subject
Immunology,Immunology and Allergy
Reference115 articles.
1. About Rare Cancers
2. What are rare cancers?
3. Cancer Facts & Figures 2022
4. Cancer statistic;Siegel;CA Cancer J Clin,2022
5. Chimera and tandem-repeat type galectins: the new targets for cancer immunotherapy;Chimera;Biomolecules,2023